Yakubov R, Kaloti R, Persaud P, McCracken A, Zadeh G, Bunda S (2025) It’s all downstream from here: RTK/RAF/MEK/ERK pathway resistance mechanisms in glioblastoma. J Neurooncol. https://doi.org/10.1007/s11060-024-04930-w

Article  PubMed  PubMed Central  Google Scholar 

Roda D, Veiga P, Melo JB, Carreira IM, Ribeiro (2024) IP: principles in the management of glioblastoma. Genes (Basel) 15(4):501

van der Graaf WTA, Blay J-Y, Chawla SP et al (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London England) 379:1879–1886

Article  PubMed  Google Scholar 

Li J, Qin S, Xu R et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16(6):619–629

Article  PubMed  CAS  Google Scholar 

Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312

Article  PubMed  CAS  Google Scholar 

Ferguson FM, Gray NS (2018) Kinase inhibitors: the road ahead. Nat Rev Drug Discov 17:353–377

Article  PubMed  CAS  Google Scholar 

Cao Y, Shan H, Liu M et al (2021) Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib. Cell Death Dis 12:396

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cao Y, Liu Y, Liu Y et al (2023) Effects of Decitabine Combined with Anlotinib on Proliferation and Apoptosis of Multiple Myeloma Cells. Zhongguo shi yan xue ye xue za zhi 31(2):442–447

PubMed  CAS  Google Scholar 

Mok TS, Wu Y-L, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

Article  PubMed  CAS  Google Scholar 

Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

Article  PubMed  CAS  Google Scholar 

Soria J-C, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125

Article  PubMed  CAS  Google Scholar 

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L (2018) Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 29:i10–i19

Article  PubMed  PubMed Central  Google Scholar 

Tomuleasa C, Tigu A-B, Munteanu R et al (2024) Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct Target Ther 9:201

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pang X, Xu W, Liang J, Liu Y, Li H, Chen L (2025) Research progress and perspectives of dual-target inhibitors. Eur J Med Chem 289:117453

Article  PubMed  CAS  Google Scholar 

Gao Y, Liu P, Shi R (2020) Anlotinib as a molecular targeted therapy for tumors. Oncol Lett 20:1001–1014

Article  PubMed  PubMed Central  CAS  Google Scholar 

Guo Z, Jing X, Sun X, Sun S, Yang Y, Cao Y (2024) Tumor angiogenesis and anti-angiogenic therapy. Chin Med J (Engl) 137:2043–2051

Article  PubMed  CAS  Google Scholar 

Lin B, Song X, Yang D, Bai D, Yao Y, Lu N (2018) Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene 654:77–86

Article  PubMed  CAS  Google Scholar 

Wang G, Sun M, Jiang Y et al (2019) Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer 145:979–993

Article  PubMed  CAS  Google Scholar 

Xu J, Chen C, Sun K et al (2023) Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma. Front Oncol 13:1–12

Google Scholar 

Yang Q, Ni L, Imani S et al (2020) Anlotinib suppresses colorectal cancer proliferation and angiogenesis via Inhibition of AKT/ERK signaling cascade. Cancer Manag Res 12:4937–4948

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li H, Feng H, Zhang T et al (2024) CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib. Mol Cancer 23:1–19

Article  CAS  Google Scholar 

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

Article  PubMed  CAS  Google Scholar 

Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

Article  PubMed  CAS  Google Scholar 

Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496

Article  PubMed  CAS  Google Scholar 

Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-bli. Lancet Oncol 16:499–508

Article  PubMed  CAS  Google Scholar 

Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (London England) 383:31–39

Article  PubMed  CAS  Google Scholar 

Garon EB, Ciuleanu T-E, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673

Article  PubMed  CAS  Google Scholar 

Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM (2017) Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies - a review. J Adv Res 8:591–605

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhao Y, Adjei AA (2015) Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 20:660–673

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liting L, Xin H, Jiaxin L et al (2024) Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer. J Biomed Res 38:1–15

Article  Google Scholar 

Lu J, Zhong H, Chu T et al (2019) Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur Respir J. https://doi.org/10.1183/13993003.01562-2018

Article  PubMed  Google Scholar 

Liang J, Jin Z, Kuang J et al (2021) The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis. Br J Cancer 125:390–401

Article  PubMed  PubMed Central  CAS